The growth of the market is attributed favorable reimbursement scenario and strong government support in selected countries, technological advancements in insulin delivery devices, and growing diabetic population. Increasing research and development activities and increase in diabetes-related health expenditure in emerging economies are expected to offer significant growth opportunities for manufacturers in the coming years.
The Insulin Delivery Devices Market is expected to reach USD 17.8 billion by 2021 from USD 11.5 billion in 2016, at a CAGR of 9.1% during the forecast period. Ask for PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092 Key Market Drivers:- 1 Growing Diabetic Population 2 Technological Advancements in Insulin Delivery Devices 3 Favorable Reimbursement Environment and Government Support in Selected Countries 4 Conferences, Meetings, and Congresses to Create Awareness About Insulin Delivery Devices Market Segmentation:- Based on type, the insulin delivery devices market is categorized into pens, pumps, pen needles, syringes, and others (insulin inhalers, transdermal patches, and insulin jet injectors, among others). In 2016, the pens segment is expected to command the largest share of the insulin delivery devices market. The pens segment is further divided into reusable and disposable pens. The reusable pens segment is estimated to command the largest share of the insulin pens market in 2016. This large share can be attributed to lower price compared to disposable pens; availability of reimbursement in selected countries, and increasing adoption of insulin pens in the Asia-Pacific region. By end user, the insulin delivery devices market is segmented into patients/homecare and hospitals & clinics. The patients/homecare segment is estimated to command the largest share of the market in 2016 and is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be primarily attributed to the increasing diabetic population and rising healthcare expenditure. Regional Analysis: - In 2016, North America is expected to account for the largest share of the global insulin delivery devices market. North America’s leadership position in the market can be attributed to the rising prevalence of diabetes and favorable reimbursement scenarios in the US and Canada, awareness activities, venture capital investments and issuance of IPOs in the US, and regulations for the usage of safety-engineered needles in Canada. Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=107632092 Top Key Players :- The insulin delivery devices market is highly competitive with the presence of several small and big players. Some of the players in the insulin delivery devices market include Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Medtronic plc (Ireland), Animas Corporation (US), Tandem Diabetes Care, Inc. (US), Sanofi (France), Biocon Ltd. (India), Eli Lilly and Company (US), and Insulet Corporation (US).
0 Comments
The growth of this market is majorly attributed to the development of regulations for transaction processes, the rising need to curtail healthcare costs and government support for HCIT implementation. Also, the need for the efficient management of electronic claims and reimbursement transactions (for healthcare providers) is expected to drive demand growth in the healthcare EDI market during the forecast period.
The report Healthcare EDI Market is projected to reach USD 4.4 billion by 2025 from USD 3.0 billion in 2020, at a CAGR of 7.8% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=130571438 By delivery mode, the mobile EDI segment is expected to grow at the highest growth rate during the forecast period Among the delivery mode segment, the mobile EDI segment is expected to grow at the highest CAGR during the forecast period. The factors attributing to the high growth of this segment include the technological upgrades in the healthcare industry and growing acceptance of mobile solutions among healthcare providers. By component, the services segment is expected to record the highest CAGR during the forecast period The services segment is expected to witness a faster growth rate in this market due to factors such as, the increasing claims volume, increasing complexity, and scale of EDI solutions, as they require extensive training programs. Similarly, a growing trend of outsourcing activities, such as revenue cycle management, claims handling and management, and partner management services is also expected to propel the growth of the services market. By transaction type, the claims management segment is expected to account for the largest share of the healthcare EDI market On the basis of the transaction type, the healthcare EDI market is segmented into claims management and healthcare supply chain. The claims management segment is expected to account for the largest share of the healthcare EDI market during the forecast period. The large share of this segment can be attributed to the rising adoption of EDI services by healthcare providers and payers and the need to meet regulatory requirements. By end user, the healthcare payers segment to record the highest CAGR during the forecast period Based on end user, the healthcare EDI market is segmented into healthcare providers, healthcare payers, medical device & pharmaceutical industries, and pharmacies. The healthcare payers segment is expected to grow at the highest CAGR during the forecast period due to the increasing number of private insurance players in the market. North America dominates the Healthcare EDI market during the forecast period. North America is expected to hold the largest market size in the global healthcare EDI market during the forecast period, followed by the European region. The rising HCIT expenditure, developed healthcare infrastructure, broad insurance coverage, a favorable regulatory scenario, an increasing number of private healthcare players, growing demand for healthcare supply chain management solutions, and the presence of prominent healthcare IT companies in this region, are responsible for the large share of the North American healthcare EDI market. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=130571438 Top key Players :- McKesson Corporation (US), Optum (US), Allscripts Healthcare Solutions Inc. (US), athenahealth (US), and Nextgen Healthcare (US) are the key players operating in the healthcare EDI market. Other prominent players in this market include Cognizant Technology Corporation (US), SSI Group, LLC (US), Cerner Corporation (US), Comarch SA (Poland), Axway Software SA (France), Optum Inc. (US), Dell Technologies Inc. (US), Nextgen Healthcare (US), Synnex Corporation (US), Comarch (Poland), Axway Solutions (US), and Plexis Healthcare Systems (US). Growth in this market is driven by the implementation of government initiatives supporting the adoption of HCIT solutions, advantages of clinical workflow solutions in enhancing patient care and safety, increasing patient volume due to the COVID-19 pandemic, growing adoption of EHRs and other HCIT solutions, and the rising need to curtail healthcare costs.
The Clinical Workflow Solutions Market is projected to reach USD 18.1 billion by 2025 from USD 9.1 billion in 2020, at a CAGR of 14.8% during the forecast period. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=146901412 Market Segmentation: - Based on products, the clinical workflow solutions market is segmented into workflow automation solutions, care collaboration solutions, real-time communication solutions, data integration solutions, and enterprise reporting and analytics solutions. The data integration segment is estimated to account for the largest market share in 2019. The large share of this segment can be attributed to the increasing demand for using medical records and integrating them across hospital departments has been one of the major drivers for data integration solutions. Based on end users, the clinical workflow solutions market is segmented into hospitals, long-term care facilities, and ambulatory care facilities. The hospital segment is estimated to account for the largest market share in 2019. Market Drivers: 1 Advantages of clinical workflow solutions in enhancing patient care and safety 2 Government initiatives for HCIT adoption 3 Growing adoption of EHRs and other HCIT solutions 4 Increasing patient volume due to the rising prevalence of chronic diseases and COVID-19 5 Rising need to curtail healthcare costs Regional Analysis: - North America is expected to account for the largest share of the clinical workflow solutions market in 2019, followed by Europe. The dominance of the North American region can be attributed to the growing healthcare IT spending, developed infrastructure, evolving regulations for better healthcare outcomes, and the presence of major market players in the region. Request for Sample Pages: – https://www.marketsandmarkets.com/requestsampleNew.asp?id=146901412 Top Key Players: - The prominent players in the clinical workflow solutions market are are Hill-Rom Holdings, Inc. (US), Ascom Holding AG (Switzerland), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Cisco Systems, Inc. (US), Stanley Black & Decker, Inc. (US), Cerner Corporation (US), Infor, Inc. (US), Allscripts Healthcare Solutions, Inc. (US), and McKesson Corporation (US). The growth of this market is primarily driven by the increasing global meat demand, research into alternatives to antibiotics, and the need to deal with epidemics and environmental factors. However, various countries have stringent regulations in place against antibiotics and particular growth promoters, which has affected their adoption.
The report Animal Growth Promoters and Performance Enhancers Market is projected to reach USD 18.5 billion by 2024 from an estimated USD 13.9 billion in 2019, at a CAGR of 5.9% during the forecast period. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137134167 Market Segmentations: -. Based on type, the animal growth promoters market is segmented into antibiotic and non-antibiotic growth promoters. The non-antibiotic growth promoters segment accounted for the largest share of the animal growth promoters and performance enhancers market in 2018. On the basis of animal type, the Animal Performance Enhancers Market is segmented into poultry, swine, livestock, aquaculture, and other farm animals (equine, rabbit, camel, deer, yak, and geese). In 2019, the poultry segment accounted for the largest share of the animal growth promoters and performance enhancers market. Critical questions answered in the Report: -
In 2019, the Asia Pacific region accounted for the largest market share of 36.7%, followed by North America (26.1%) in 2018. The largest share of the Asia Pacific region is attributed to the strong animal products industry in this region, high population (generating greater domestic meat demand), a comparatively relaxed regulatory scenario, and government efforts to encourage animal producers. Request for Sample Pages : - https://www.marketsandmarkets.com/requestsampleNew.asp?id=137134167 Key Players: - The key players in the global animal performance enhancers market are Merck and Co. Inc. (US), Cargill Inc. (US), Royal DSM N.V. (Germany), Vetoquinol (France), Bupo Animal Health (SA), Elanco Animal Health Inc. (US), CHR Hansen (UK), Novus International Inc. (US), Associated British Foods (ABF) plc (UK), Alltech Inc. (US), ERBER AG (UK), Archer-Daniels-Midland Company (US), Phibro Animal Health Corporation (US), Kemin Industries (US), SHV (Nutreco) (UK), BASF SE (UK), Lallemond Inc. (Canada), Bluestar Adisseo Company (France), Evonik Industries AG (UK), and Land O Lake Inc.(US). The ventilators market is projected to reach USD 1,033.3 million in 2025 from USD 6,888.5 in 2020 and is expected to grow at a CAGR of -31.6% during the forecast period. The ventilators market is expected to witness significant growth in the coming years fueled by the rising geriatric population and subsequent growth in the prevalence of chronic respiratory diseases, increasing number of preterm births, increasing number of intensive care units and the outbreak of the COVID-19 pandemic. Factors such as growing demand for homecare therapeutic devices, technological advancements and growth opportunities in emerging countries will offer several opportunities for the market.
However, dearth of skilled medical workers, reimbursement concerns, complications associated with the use of ventilators will restrain market growth to certain extent. Lack of awareness and a large population undiagnosed & undertreated patients, and harmful effects of certain devices on neonates will pose challenges for the market growth. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11018337 The global ventilators market is consolidated at the top, with many leading market players based in developed countries. The prominent players in this market are Philips Healthcare (Netherlands), ResMed Inc. (US), Medtronic plc (Ireland), Fisher & Paykel Healthcare Corporation Limited (New Zealand), Drägerwerk AG & CO. KGAA (Germany), Nihon Kohden Corporation (Japan), Getinge AB (Sweden), Asahi Kasei Corporation (Japan), Air Liquide (France), Vyaire Medical, Inc. (US), GE Healthcare (US), Hamilton Medical (Switzerland), Smiths Group plc (UK), Allied Healthcare Products, Inc. (US), Shenzhen Mindray Bio-Medical Electronics Co., Ltd, (China), aXcent Medical GmbH (Germany), Metran Co., Ltd (Japan), MAGNAMED (Brazil), Avasarala Technologies Ltd (India), Airon Corporation (Florida), TRITON Electronic Systems Ltd. (Russia), Bio-Med Devices, Inc. (US), Hill-Rom Holdings, Inc. (US), HEYER Medical AG (Germany), and Leistung (Argentina). However, several smaller players have emerged from niche markets in the past few years, competing with global players based on price and service offering. Due to intense competition in the market, major market players increasingly focus on expanding their geographic presence into high-growth emerging markets and strengthening their technological competitiveness by acquiring smaller players with the desired technological capabilities or geographical presence. Based on the mobility, the ventilators market is segmented into intensive care and portable/transportable ventilators. In 2019, the intensive care ventilators segment accounted for largest share of the ventilators market. The large share of the intensive care ventilators segment can be attributed to the rising number of intensive care beds equipped with ventilators. The increasing ICU admission due to COVID-19 and re-admissions in developed countries coupled with appropriate reimbursement is also responsible for the large share of the ICU ventilators segment Based on the interface, the ventilators market is segmented into invasive ventilation and non-invasive ventilation. In 2019, the invasive ventilation segment accounted for largest share of the ventilators market. Growth in the invasive ventilation market can be attributed to increasing severity in COVID-19 patients and the rising prevalence of respiratory diseases, neurological diseases, and sleeping disorders. On the basis of end user, the ventilators market is segmented into hospitals and clinics, home care, ambulatory care centers, and emergency medical services based on end users. Hospitals and clinics are the major end users of ventilators. This can largely be attributed to hospitals' financial capabilities to purchase high-priced instruments as well as the availability of trained professionals to operate ventilators Request for Sample Pages : - https://www.marketsandmarkets.com/requestsampleNew.asp?id=11018337 Based upon region, the ventilators market is broadly segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2019, North America accounted for the largest share of the ventilators market, followed by Europe, Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America is primarily due to the presence of major manufacturers in this region, such as Vyaire Medical (US), GE Healthcare (US), ZOLL Medical (US), and ResMed (US). In addition to the presence of major market players, the rising geriatric population, increasing COVID-19 patient volume, high prevalence of smoking, high prevalence of respiratory diseases, highly developed healthcare system, and high healthcare expenditure are the other factors responsible for the large share of North America in the ventilators market. Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants. However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.
The global Stem Cell Therapy Market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48 Market Segmentation: - The adipose tissue-derived MSCs segment accounted for the largest share of the cell source segment in the stem cell therapy market in 2020. Based on the cell source from which stem cells are obtained, the global stem cell therapy market is segmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which includes human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines). In 2020, adipose tissue-derived MSCs accounted for the markets largest share due to their increasing utilization in treating inflammatory diseases and wounds & injuries. There are several associated advantages, such as ease of harvesting stem cells by minimally invasive methods, simplicity of the isolation procedure, and better quality & proliferation capacity of adipose tissue-derived stem cells. The musculoskeletal disorders segment accounted for the largest share of the therapeutic application segment in the stem cell therapy market in 2020 Based on therapeutic application, the global stem cell therapy market is segmented into musculoskeletal disorders, wounds & injuries, cardiovascular diseases, surgeries, inflammatory & autoimmune diseases, neurological disorders, and other therapeutic applications (which include ocular diseases, fat loss, and peripheral arterial diseases). In 2020, the musculoskeletal disorders segment accounted for the largest share of the therapeutic application segment. The large market share of this segment is attributed to the increasing prevalence of musculoskeletal disorders such as osteoarthritis, bone repair, and regeneration. Regional Analysis: - The Asia Pacific region is the fastest-growing region of the stem cell therapy market in 2020. The Asia Pacific region is estimated to grow at the highest CAGR in the stem cell therapy market during the forecast period. Some of the major factors fueling the growth of the APAC market include regulatory approvals and guidelines for product approvals and the presence of major stem cell players in countries such as South Korea, Japan, India, and Australia. Request for Sample Pages :-https://www.marketsandmarkets.com/requestsampleNew.asp?id=48 Top Key Players: - Key players in the stem cell therapy market include Smith & Nephew (UK), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), PHARMICELL Co., Ltd. (South Korea), JCR Pharmaceuticals Co., Ltd. (Japan), and NuVasive, Inc. (US). The growth of this market is mainly attributed to the shift toward computerized registries from paper-based registries, due to their advantages, is a key driver of market growth. The emergence of the COVID-19 pandemic and the increase in the number of COVID-19 patients globally is also expected to support the demand for patient registry software.
The report Patient Registry Software Market is projected to reach USD 2.4 billion by 2025 from USD 1.2 billion in 2020, at a CAGR of 14.4% from 2020 to 2025. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144694594 Market Segmentation:- Based on the type of registry, the patient registry software market is segmented into product registries, health service registries, and disease registries. The disease registries segment accounted for the largest share of 67.2% of the patient registry software market in 2019. Based on the deployment model, the Patient Registry Software Industry is segmented into on-premise model and cloud-based model. In 2019, on-premise models held 82.6% of the global patient registry software market. The large share of this segment can be attributed to the enhanced control and safety of patient data, and the large number of COVID-19 patients across the globe, which has driven the demand for registries. Based on functionality, the population health management (PHM) segment accounted for the largest market share of 28.9% in 2019. The large share of this segment can be primarily attributed to the implementation of favorable regulations, such as the ACA in the US. Based on the end user, the Patient Registry Software Industry is segmented into private payers; hospitals & medical practices; research centers; pharmaceutical, biotechnology, & medical device companies; and government organizations & TPAs. In 2019, the government organizations & TPAs segment accounted for the largest share of 33.9% of the global patient registry software market. Recent Developments
The patient registry software market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2019, North America accounted for the largest share of 48.9% of the global patient registry software market. Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=144694594 Top key Players: - Some of the prominent players in this market are Phytel, Inc. (US), IQVIA Holdings, Inc. (US), OpenText Corporation (Canada), ImageTrend, Inc. (US), FIGmd, Inc. (US), Syneos Health Inc. (US) and McKesson Corporation (US). The rapid growth in the geriatric population, rising prevalence of eye diseases, and technological advancements in ophthalmic devices are the major factors driving the growth of this market.
The Ophthalmic Equipment Market size is projected to reach USD 63.3 billion by 2025 from USD 52.8 billion in 2020, at a CAGR of 3.7% during the forecast period. Ask for PDF Brochure: –https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155637364 Market Segmentation: - Based on product, the ophthalmic equipment market is categorized mainly into diagnostic & monitoring devices, surgical devices, and vision care products. In 2019, the vision care products segment was expected to account for the largest share of the ophthalmic equipment market. The large share of this segment can primarily be attributed to the high prevalence of eye disorders such as myopia, hyperopia, astigmatism, and presbyopia. In addition to this, technological advancements in lens materials, growing awareness about eyesight correction, and rising trends in eyewear, such as styled sunglasses and advanced contact lenses boasting extra comfort, have further stimulated the adoption of vision care products. Recent Developments
Based on end-user, the ophthalmic equipment market is segmented into consumers, hospitals, specialty clinics & ambulatory surgery centers (ASCs), and other end users. specialty clinics & ambulatory surgery centers (ASCs) are expected to grow at the highest CAGR during the forecast period. Regional Analysis: - North America is expected to account for the largest share of the ophthalmic equipment market in 2019, followed by Europe. In addition, factor such as the growing awareness and uptake of ophthalmic treatments and surgeries and the availability of advanced ophthalmic devices in this region are also driving the growth of the ophthalmic equipment market in North America. Request for Sample Pages :- https://www.marketsandmarkets.com/requestsampleNew.asp?id=155637364 Top Key Players:- The prominent players in this market are EssilorLuxottica (France), Alcon (US), Johnson & Johnson Vision Care (US), HOYA Corporation (Japan), Bausch + Lomb (US), Carl Zeiss Meditec (Germany), Topcon (Japan), Glaukos Corporation (US), Haag-Streit (Switzerland), NIDEK (Japan), STAAR Surgical (US), Ziemer Ophthalmic Systems (Switzerland), CooperVision, Inc. (US), Oculentis (Germany), Heidelberg Engineering (Germany), Canon (Japan), Optovue (US), Neo Vision (Korea), Lumenis (Israel), Reichert Technologies (US), OPHTEC BV (Netherlands), Heine Optotechnik (Germany), and Luneau Technology (France). Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.
The Molecular Quality Controls Market is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period. Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523 Market Segmentation:- Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls. The independent controls segment accounted for a larger share of the molecular controls market in 2018. The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations. By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls. Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity. Recent Developments:-
North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523 Top Key Players:- The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US). Factors such as the growing incidence of urolithiasis and technological advancements in lithotripsy devices are driving the growth of this market.
The report Lithotripsy Devices Market is expected to reach USD 1.76 Billion by 2023 from USD 1.41 Billion in 2018, at a CAGR of 4.5%. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=29769904 Market Segmentation:- By type, the lithotripsy devices market is classified into extracorporeal shock wave lithotripsy devices and intracorporeal lithotripsy devices. In 2017, the extracorporeal shock wave lithotripsy devices segment accounted for the largest share of the market. ESWL is the least invasive of all stone treatments and is considered the treatment modality of choice for a majority of urinary stones. On the basis of applications, the lithotripsy devices market is categorized into kidney stones, ureteral stones, pancreatic stones, and bile duct stones. In 2017, the kidney stones segment accounted for the largest share of the market. The increasing incidence of kidney stones and the recurrence of these stones over a period of time are the key factors driving the growth of this segment. On the basis of end user, the lithotripsy devices market is categorized into hospitals, ambulatory surgical centers, and other end users. In 2017, the hospitals segment accounted for the largest share of the global lithotripsy devices market. Target Audience for this Report:-
Based on region, the lithotripsy devices market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America dominated the lithotripsy devices market in 2017. The large share can primarily be attributed to the high prevalence of kidney stones and the large number of surgeries performed each year. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=29769904 Top key Players:- Some of the major players in the lithotripsy devices market are Siemens AG (Germany), Boston Scientific (US), Dornier MedTech (Germany), Olympus America (Japan), DirexGroup (Germany), and Richard Wolf (Germany). |
AuthorWe are providing and consulting the healthcare Industry Research Report. Archives
March 2022
Categories |